Comparison · NCT01920893-sae
Dupilumab 300 mg QW vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dupilumab 300 mg QW vs Placebo: serious adverse events. Trial comparisons, record NCT01920893-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01920893-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0667 | 0.0185 | 0.213 | wilson | |
| Risk in group 2 | 0.133 | 0.0531 | 0.297 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0667 | -0.237 | 0.1 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.0989 | 2.53 | log | |
| Odds ratio, group 1 over group 2 | 0.464 | 0.0783 | 2.75 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Dupilumab 300 mg QW than on Placebo | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dupilumab 300 mg QW | Participants exposed to dupilumab added to MFNS (mean exposure of 16 weeks). | 2 | 30 | EG001 |
| Group 2 | Placebo | Participants exposed to placebo (for dupilumab) added to MFNS (mean exposure of 14 weeks). | 4 | 30 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational medicinal product (IMP).
Source ClinicalTrials.gov
Trial
- Title
- An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
- NCT number
- NCT01920893
- Phases
- PHASE2
- Conditions
- Nasal Polyps
- Interventions
- Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray
- Lead sponsor
- Sanofi
- Results first posted
- 2017-06-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01920893?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01920893-sae